Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec

Eskazan A. E., Sadri S., Keskin D., Ayer M., Kantarcioglu B., Demirel N., ...More

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.17, no.12, pp.804-811, 2017 (SCI-Expanded) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 17 Issue: 12
  • Publication Date: 2017
  • Doi Number: 10.1016/j.clml.2017.07.255
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.804-811
  • Keywords: BCR-ABL1, CML, Generic imatinib, Outcome, Response, CHRONIC PHASE, MANAGEMENT, MESYLATE, CML
  • Acibadem Mehmet Ali Aydinlar University Affiliated: Yes


We retrospectively evaluated 90 patients with chronic myeloid leukemia receiving either upfront original imatinib (Ol) or generic imatinib (Gl) for the effect of the early molecular response on the long-term outcome. We demonstrated that achieving an optimal response at 3 and 6 months in patients receiving either first-line Gl or Ol was clearly associated with greater response and event-free survival rates.